Alerts will be sent to your verified email
Verify EmailSEQUENT
Sequent Scientific
|
Zota Health Care
|
Guj. Themis Biosyn
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
0.0 | 0.09 % | n/a |
Financials
|
|||
5 yr Average ROE
|
-0.13 % | -7.74 % | 34.65 % |
5yr average Equity Multiplier
|
2.16 | 1.84 | 1.29 |
5yr Average Asset Turnover Ratio
|
0.95 | 0.91 | 0.74 |
5yr Avg Net Profit Margin
|
0.03 % | -4.95 % | 35.51 % |
Price to Book
|
7.17 | 19.8 | 16.92 |
P/E
|
170.21 | 0.0 | 94.23 |
5yr Avg Cash Conversion Cycle
|
49.09 Days | 40.5 Days | -112.39 Days |
Inventory Days
|
80.25 Days | 91.82 Days | 22.82 Days |
Days Receivable
|
79.76 Days | 42.2 Days | 70.51 Days |
Days Payable
|
114.46 Days | 92.36 Days | 130.88 Days |
5yr Average Interest Coverage Ratio
|
1.93 | 5.98 | 216.76 |
5yr Avg ROCE
|
6.67 % | -2.72 % | 45.66 % |
5yr Avg Operating Profit Margin
|
7.74 % | 3.69 % | 47.34 % |
5 yr average Debt to Equity
|
0.53 | 0.04 | 0.03 |
5yr CAGR Net Profit
|
-25.52 % | 206.06 % | 10.07 % |
5yr Average Return on Assets
|
0.05 % | -3.4 % | 26.69 % |
Shareholdings
|
|||
Promoter Holding
|
52.61 % | 57.42 % | 70.86 % |
Share Pledged by Promoters
|
0.0 | 0.26 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.18 % | -10.7 % | -4.13 % |
Change in Mutual Fund Holding (3 Yrs)
|
9.79 % | 0.0 | 1.14 % |
Sequent Scientific
|
Zota Health Care
|
Guj. Themis Biosyn
|
|
---|---|---|---|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Customer Segment
|
Customer Segment
|
-
|
-
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
R&D Break-Up - Product Wise
|
R&D Break-Up - Product Wise
|
-
|
-
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|
Species Break-Up
|
Species Break-Up
|
-
|
-
|